Cell-Free DNA Methylation as Blood-Based Biomarkers for Pancreatic Adenocarcinoma-A Literature Update

Pancreatic adenocarcinoma has a horrible prognosis, which is partly due to difficulties in diagnosing the disease in an early stage. Additional blood-born biomarkers for pancreatic adenocarcinoma are needed. Epigenetic modifications, as changes in DNA methylation, is a fundamental part of carcinogen...

Full description

Saved in:
Bibliographic Details
Published in:Epigenomes 2021-04, Vol.5 (2), p.8
Main Authors: Henriksen, Stine Dam, Thorlacius-Ussing, Ole
Format: Article
Language:English
Subjects:
Adenocarcinoma
Biomarkers
Biopsy
Blood
Cancer
Carcinogenesis
Deoxyribonucleic acid
diagnostic biomarker
DNA
DNA methylation
epigenetic
Epigenetics
Gallstones
Gene expression
Medical prognosis
Metastasis
Pancreas
pancreatic cancer
pancreatic ductal adenocarcinoma
Pancreatitis
Plasma
prognostic biomarker
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pancreatic adenocarcinoma has a horrible prognosis, which is partly due to difficulties in diagnosing the disease in an early stage. Additional blood-born biomarkers for pancreatic adenocarcinoma are needed. Epigenetic modifications, as changes in DNA methylation, is a fundamental part of carcinogenesis. The aim of this paper is to do an update on cell-free DNA methylation as blood-based biomarkers for pancreatic adenocarcinoma. The current literature including our studies clearly indicates that cell-free DNA methylation has the potential as blood-based diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. However, still no clinical applicable biomarker for pancreatic adenocarcinoma based on DNA methylation do exist. Further well-designed validation studies are needed.
ISSN:2075-4655
2075-4655
DOI:10.3390/epigenomes5020008